Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
I-Mab Biopharma
company
About
I-Mab is a dynamic and fast-growing global biotech company exclusively focused on developing innovative biologics.
- 51 - 100
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $220M
- Industries
- Biotechnology,Pharmaceutical,Product Research
- Founded date
- Jan 1, 2016
- Number Of Employee
- 51 - 100
- Operating Status
- Active
I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders..
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$220M
I-Mab Biopharma has raised a total of
$220M
in funding over 2 rounds. Their latest funding was raised on
Jun 29, 2018 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 29, 2018 | Series C | $220M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
I-Mab Biopharma is funded by 2 investors.
Tally Capital
and HOPU Investment Management Company
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Tally Capital
|
— | Series C |
|
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
